Clinical significance of MART-1 and HLA-A2 expression and CD8+ T cell infiltration in melanocytic lesions in HLA-A2 phenotype patients

Toshiro Kageshita, Yutaka Kawakami, Tomomichi Ono

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

MART-1 is a good candidate antigen for immunotherapy against HLA-A2 patients with melanoma, since it is a highly immunogenic antigen recognized by HLA-A2 and HLA-B45 restricted CD8+ cytotoxic T cells and expressed in the majority of melanoma lesions. In the present study the expression of MART-1 and HLA-A2 on melanocytic cells and CD8+ T cell infiltration was immunohistochemically analyzed. MART-1 was expressed in most melanocytic lesions, while HLA-A2 was down-regulated with melanoma disease progression. Furthermore, concomitant down-regulation of MART-1 and HLA-A2 in melanoma cells was corrrelated with poor prognosis. These findings suggest both MART-1 and HLA-A2 expression in melanoma lesions should be analyzed for selection of patients eligible for MART-1 based immunotherapy and monitoring for emergence of melanoma cells resistant to T cell therapy.

Original languageEnglish
Pages (from-to)36-44
Number of pages9
JournalJournal of Dermatological Science
Volume25
Issue number1
DOIs
Publication statusPublished - 2001

Fingerprint

HLA-A2 Antigen
T-cells
Infiltration
Melanoma
T-Lymphocytes
Phenotype
Immunotherapy
Antigens
Cell- and Tissue-Based Therapy
Patient Selection
Disease Progression
Down-Regulation
Monitoring

Keywords

  • CD8+ T cell
  • Down-regulation
  • HLA-A2
  • MART-1
  • Melanoma

ASJC Scopus subject areas

  • Dermatology

Cite this

Clinical significance of MART-1 and HLA-A2 expression and CD8+ T cell infiltration in melanocytic lesions in HLA-A2 phenotype patients. / Kageshita, Toshiro; Kawakami, Yutaka; Ono, Tomomichi.

In: Journal of Dermatological Science, Vol. 25, No. 1, 2001, p. 36-44.

Research output: Contribution to journalArticle

@article{b113f59a99244c0ab091c84d72b0159e,
title = "Clinical significance of MART-1 and HLA-A2 expression and CD8+ T cell infiltration in melanocytic lesions in HLA-A2 phenotype patients",
abstract = "MART-1 is a good candidate antigen for immunotherapy against HLA-A2 patients with melanoma, since it is a highly immunogenic antigen recognized by HLA-A2 and HLA-B45 restricted CD8+ cytotoxic T cells and expressed in the majority of melanoma lesions. In the present study the expression of MART-1 and HLA-A2 on melanocytic cells and CD8+ T cell infiltration was immunohistochemically analyzed. MART-1 was expressed in most melanocytic lesions, while HLA-A2 was down-regulated with melanoma disease progression. Furthermore, concomitant down-regulation of MART-1 and HLA-A2 in melanoma cells was corrrelated with poor prognosis. These findings suggest both MART-1 and HLA-A2 expression in melanoma lesions should be analyzed for selection of patients eligible for MART-1 based immunotherapy and monitoring for emergence of melanoma cells resistant to T cell therapy.",
keywords = "CD8+ T cell, Down-regulation, HLA-A2, MART-1, Melanoma",
author = "Toshiro Kageshita and Yutaka Kawakami and Tomomichi Ono",
year = "2001",
doi = "10.1016/S0923-1811(00)00104-3",
language = "English",
volume = "25",
pages = "36--44",
journal = "Journal of Dermatological Science",
issn = "0923-1811",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Clinical significance of MART-1 and HLA-A2 expression and CD8+ T cell infiltration in melanocytic lesions in HLA-A2 phenotype patients

AU - Kageshita, Toshiro

AU - Kawakami, Yutaka

AU - Ono, Tomomichi

PY - 2001

Y1 - 2001

N2 - MART-1 is a good candidate antigen for immunotherapy against HLA-A2 patients with melanoma, since it is a highly immunogenic antigen recognized by HLA-A2 and HLA-B45 restricted CD8+ cytotoxic T cells and expressed in the majority of melanoma lesions. In the present study the expression of MART-1 and HLA-A2 on melanocytic cells and CD8+ T cell infiltration was immunohistochemically analyzed. MART-1 was expressed in most melanocytic lesions, while HLA-A2 was down-regulated with melanoma disease progression. Furthermore, concomitant down-regulation of MART-1 and HLA-A2 in melanoma cells was corrrelated with poor prognosis. These findings suggest both MART-1 and HLA-A2 expression in melanoma lesions should be analyzed for selection of patients eligible for MART-1 based immunotherapy and monitoring for emergence of melanoma cells resistant to T cell therapy.

AB - MART-1 is a good candidate antigen for immunotherapy against HLA-A2 patients with melanoma, since it is a highly immunogenic antigen recognized by HLA-A2 and HLA-B45 restricted CD8+ cytotoxic T cells and expressed in the majority of melanoma lesions. In the present study the expression of MART-1 and HLA-A2 on melanocytic cells and CD8+ T cell infiltration was immunohistochemically analyzed. MART-1 was expressed in most melanocytic lesions, while HLA-A2 was down-regulated with melanoma disease progression. Furthermore, concomitant down-regulation of MART-1 and HLA-A2 in melanoma cells was corrrelated with poor prognosis. These findings suggest both MART-1 and HLA-A2 expression in melanoma lesions should be analyzed for selection of patients eligible for MART-1 based immunotherapy and monitoring for emergence of melanoma cells resistant to T cell therapy.

KW - CD8+ T cell

KW - Down-regulation

KW - HLA-A2

KW - MART-1

KW - Melanoma

UR - http://www.scopus.com/inward/record.url?scp=0035188260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035188260&partnerID=8YFLogxK

U2 - 10.1016/S0923-1811(00)00104-3

DO - 10.1016/S0923-1811(00)00104-3

M3 - Article

C2 - 11154862

AN - SCOPUS:0035188260

VL - 25

SP - 36

EP - 44

JO - Journal of Dermatological Science

JF - Journal of Dermatological Science

SN - 0923-1811

IS - 1

ER -